Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis
Authors:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 145, 197-209
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute
This publication has 36 references indexed in Scilit:
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableJournal for ImmunoTherapy of Cancer, 2019
- The evolving landscape of biomarkers for checkpoint inhibitor immunotherapyNature Reviews Cancer, 2019
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockadeNature Medicine, 2018
- Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre studyPLOS ONE, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisThe Lancet Oncology, 2018
- Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markersBritish Journal of Cancer, 2017
- Predictive biomarkers for checkpoint inhibitor-based immunotherapyThe Lancet Oncology, 2016
- The Obesity Paradox in Cancer: a ReviewCurrent Oncology Reports, 2016
- Estimating population attributable fractions to quantify the health burden of obesityAnnals of Epidemiology, 2015